Vitamin K2 That Reactivates Bones in Menopause

A meta-analysis of 2,570 patients demonstrates significant effects on osteocalcin, BAP, and TRAP

There is a moment when bones stop making news. They signal no pain in the early stages, produce no unequivocal signs. Bone tissue deteriorates in silence, and often the first clinical evidence arrives with a fragility fracture: an event that can permanently alter a patient’s functional independence.

Osteoporosis affects nearly one in four women globally. In menopausal women, the decline in estrogen progressively accelerates bone resorption. Biochemical markers of bone metabolism become essential tools for understanding whether and how much the tissue is responding to treatment.

Vitamin K2 has long been associated primarily with coagulation. However, more recent literature has redefined its biological profile: K2 plays a precise role in calcium metabolism and bone mineralization, through mechanisms that go well beyond simple hemostasis.

A meta-analysis published in Frontiers in Endocrinology in November 2025 quantified these effects in a sample of 2,570 patients with postmenopausal osteoporosis, analyzing 9 randomized controlled trials conducted primarily in China and Japan.

Osteocalcin carboxylation: the mechanism that changes the bone picture

To understand why vitamin K2 is relevant for bones, we must start with osteocalcin: a protein produced by osteoblasts that actively participates in the mineralization of the bone matrix. To perform this function, it needs to be activated through a process called γ-carboxylation.

This is where vitamin K2 comes in: it acts as a cofactor for the enzyme responsible for this activation. When K2 is deficient or insufficient, osteocalcin remains in its non-activated form (defined as ucOC) and cannot bind effectively to bone. Elevated levels of ucOC in the blood are a signal that bone metabolism is not functioning optimally.

Vitamin K2, particularly in the MK-4 and MK-7 forms, also helps reduce the activity of osteoclasts, the cells responsible for bone resorption. The overall result is an action that promotes bone formation and, to a lesser extent, slows its breakdown.

What the meta-analysis reveals: bone formation markers respond

The review analyzed the effects of vitamin K2 on various biochemical markers. The most significant results concern bone formation markers, i.e., the substances that signal osteoblast activity. The main positive signals emerging from the trials:

• Total osteocalcin (OC): significantly and consistently increased across all included studies, confirming greater osteoblast activity
• Bone alkaline phosphatase (BAP): also increased, a further indicator of more active bone metabolism on the formation side
• Undercarboxylated osteocalcin (ucOC): markedly reduced, a signal that K2 is performing its function of activating osteocalcin

The reduction in ucOC is perhaps the most interesting finding. It does not measure a generic effect, but the specific ability of vitamin K2 to do what it is meant to do: activate the proteins that bone tissue uses to mineralize.

Resorption markers: a more nuanced picture

On the bone resorption side, the results are more complex. TRAP, a marker of osteoclast activity, showed a significant reduction in most studies: a signal that K2 helps slow bone breakdown, even though this is not its primary mechanism.

The other two resorption markers tested, CTX and NTX, showed minimal or non-significant changes. This is not necessarily a negative result: the researchers explain that these markers are less sensitive to K2’s effects for several reasons.

The three main explanations proposed by the authors:

• K2 acts primarily on bone formation, not resorption: it is physiologically normal for breakdown markers to be less reactive
• CTX is a highly variable marker (affected by time of day and meals), which can mask real effects when comparing groups
• Most studies included co-supplementation with calcium and vitamin D, which already reduces resorption on its own: it is difficult to measure the additional effect of K2 on a system already partially compensated

The overall picture that emerges is therefore that of a vitamin with an action predominantly oriented toward stimulating bone formation, rather than inhibiting resorption.

MK-4 or MK-7? What matters in product design

Not all forms of vitamin K2 behave the same way. The differences between MK-4 and MK-7 mainly concern duration of action: MK-7 has a longer serum half-life and can reach extrahepatic tissues, including bone tissue, more effectively.

The subgroup data from the meta-analysis offer useful insights for formulation:

• Dosage: studies with higher doses (around 45 mg/day) showed greater effects on osteocalcin compared to lower dosages, suggesting a dose-dependent relationship
• Treatment duration: trials with at least 6 months of intervention produced more consistent and stable results than shorter ones
• Therapeutic background: the presence of bisphosphonates in the control group reduced heterogeneity between studies, suggesting that the clinical context influences the response to K2

Bones don’t speak, but biochemical markers do. If osteocalcin rises and ucOC falls, it means the tissue is receiving what it needs: this is not a promise, it is physiology documented in nine trials on thousands of patients. Translating this biology into a well-formulated product, choosing the right vitamer, the appropriate dosage and a sufficiently long cycle, is the step that separates a generic supplement from one that produces a measurable effect on bone metabolism.

If your company is interested in developing vitamin K2-based formulations